
Fulgent Genetics (FLGT) Stock Forecast & Price Target
Fulgent Genetics (FLGT) Analyst Ratings
Bulls say
Fulgent Genetics Inc. demonstrates a strong financial outlook supported by its proprietary gene probes, which offer significant cost and flexibility advantages compared to competitors relying on third-party kits. The company’s dual focus on laboratory services and therapeutic development positions it well within the growing market for genetic testing and cancer treatment, providing a diversified revenue stream. Additionally, Fulgent's majority revenue generation from the United States enhances its market stability and potential for continued growth.
Bears say
Fulgent Genetics faces a challenging landscape as it seeks to scale its oncology business, with potential deterioration in service quality during nationwide rollouts posing a significant risk. Additionally, competitive pressures from other core market players, who may enhance their offerings and customer service, threaten to negatively impact Fulgent's operating results and relative market strength. The company is also susceptible to unpredictable regulatory changes and volatile industry fundamentals, which could adversely affect expected revenues and earnings.
This aggregate rating is based on analysts' research of Fulgent Genetics and is not a guaranteed prediction by Public.com or investment advice.
Fulgent Genetics (FLGT) Analyst Forecast & Price Prediction
Start investing in Fulgent Genetics (FLGT)
Order type
Buy in
Order amount
Est. shares
0 shares